Suspension injection for cow mastitis and preparation method thereof

By using organic solvents and other auxiliary agents, stable suspension injection for cow mastitis was formed, which solved the problem of short storage time of sacillin hydroiodate in aqueous solution, improved product quality and treatment effect, and achieved efficient Treatment of cow mastitis.

CN118903003APending Publication Date: 2024-11-08RUICHENG LVMAN BIOLOGICAL PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410967509.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing sacillin hydroiodate is stored in aqueous solution for a short time, resulting in unstable product quality of suspension injection for cow mastitis, and low absorption rate in cows, which makes the treatment effect poor.

Method used

Organic solvents are used as carriers for blastocylin or blastocylin hydroiodic acid, combined with surfactants, surf modifiers, anticorrosion inhibitors, stabilizers, thixotropic agents and local anesthetics to form a stable suspension injection solution. Prolong the effectiveness of the drug, improve bioavailability and therapeutic effect.

Benefits of technology

The product quality of the suspension injection for cow mastitis has been achieved, which reduces the stress of cows, improves the absorption rate and treatment effect of drugs, and has good application value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004952181320000091
    Figure BDA0004952181320000091
  • Figure BDA0004952181320000101
    Figure BDA0004952181320000101
Patent Text Reader

Abstract

The invention relates to the technical field of veterinary drugs, and provides a suspension injection for cow mastitis and a preparation method of the suspension injection. The environment-friendly coating is prepared from the following raw materials: 4 to 8 parts of an active component, 80 to 100 parts of an organic solvent, 4 to 8 parts of a surfactant, 2 to 4 parts of a surface modifier, 1 to 2 parts of a stabilizer, 0.5 to 1.5 parts of an anti-corrosion bacteriostatic agent, 0.2 to 0.8 part of a thixotropic agent, 0.2 to 0.5 part of an antioxidant and 0.2 to 0.4 part of a local anesthetic, wherein the active component is penicillin or penicillin hydriodate, and the active component is penicillin or penicillin hydriodate. The suspension injection provided by the invention is stable in product quality, and various indexes are not influenced; meanwhile, stress of the dairy cow is reduced, the absorption rate in the dairy cow body is high, the treatment effect on the dairy cow mastitis is good, and good application value is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of veterinary drugs, and particularly relates to a suspension injection for treating cow mastitis and a preparation method thereof. Background Art

[0002] As a new generation of penicillin antibiotics, compared with other similar drugs, pentosan has low toxicity and side effects, no drug resistance, and significant efficacy. It only requires intramuscular injection and is easy to use. The drug can maintain its antibacterial effect for more than 24 hours and is often used for intramuscular injection to treat cow mastitis.

[0003] Pentoxacillin is non-polar and has better compatibility with the lipid structure of the cell membrane, and can pass through the cell membrane more easily. This lipophilicity allows pentoxacillin to maintain a non-ionized form at a higher ratio in plasma and tissues, thereby improving its bioavailability in the body. Secondly, the lipophilicity of pentoxacillin also helps it pass through biological barriers, such as endothelial cells and tissue barriers, to reach the site of infection. Once it reaches the site of infection, pentoxacillin will release the active ingredient, benzylpenicillin, under the hydrolysis of the local environment. This local release mechanism allows pentoxacillin to reach a higher concentration at the site of infection, thereby more effectively inhibiting and killing pathogens. Although the lipophilicity and weak alkalinity of pentoxacillin give it good bioavailability and tissue penetration in the treatment of infection, pentoxacillin is extremely easy to hydrolyze in aqueous solution, is not easy to store, needs to be prepared and used immediately, and may cause uneven dispersion during preparation.

[0004] Chinese patent CN 116637070A discloses a pentaxacillin hydroiodide suspension injection and a preparation method thereof, comprising pentaxacillin hydroiodide suspension dry powder and a diluent, wherein the diluent comprises injection water and an antibacterial agent; the pentaxacillin hydroiodide suspension dry powder is prepared from pentaxacillin hydroiodide raw material, an emulsifier or dispersant, a wetting agent and a pH regulator. However, in this invention, the storage time of pentaxacillin hydroiodide in aqueous solution is relatively short.

[0005] Therefore, it is urgent to develop a suspension injection for cow mastitis, so that the suspension injection not only has stable product quality, but also has a good therapeutic effect on cow mastitis. Summary of the invention

[0006] In view of the existing technical problems, the purpose of the present invention is to provide a suspension injection for cow mastitis and a preparation method thereof. The suspension injection product of the present invention has stable quality and various indicators are not affected; at the same time, it reduces the stress of cows, has a high absorption rate in the cow's body, has a good therapeutic effect on cow mastitis, and has good application value.

[0007] In order to achieve the above object, the technical solution adopted by the present invention is as follows:

[0008] On the one hand, the present invention provides a suspension injection for bovine mastitis, which comprises the following raw materials in parts by weight: 4-8 parts of active components, 80-100 parts of organic solvents, 4-8 parts of surfactants, 2-4 parts of surface modifiers, 1-2 parts of stabilizers, 0.5-1.5 parts of preservatives and antibacterial agents, 0.2-0.8 parts of thixotropic agents, 0.2-0.5 parts of antioxidants and 0.2-0.4 parts of local anesthetics; wherein the active component is pentothaline or pentothaline hydroiodide.

[0009] The reaction mechanism and effects of the present invention are as follows:

[0010] 1. The active component (pentoxaline or pentoxaline hydroiodide) is unstable when in contact with water and is easily hydrolyzed. The applicant uses an organic solvent to replace water as a carrier of the active component, which can extend the shelf life of the drug while ensuring activity and reducing losses caused by environmental changes. At the same time, the oily organic solvent propylene glycol dicaprylate / dicaprate and caprylic / capric triglyceride are selected as carriers of pentoxaline or pentoxaline hydroiodide to increase the solubility of pentoxaline. Further, the applicant controls the mass ratio of propylene glycol dicaprylate / dicaprate and caprylic / capric triglyceride to achieve sustained release or controlled release of the drug, thereby achieving a more lasting therapeutic effect. In addition, the use of organic solvents as carriers is highly safe and can be adjusted according to treatment needs, providing more flexibility for drug formulations.

[0011] 2. Sodium methyl parahydroxybenzoate destroys the cell membrane structure of microorganisms, denatures the proteins in the cells, and inhibits the activity of the respiratory enzyme system and electron transfer enzyme system of microbial cells, thereby inhibiting or killing bacteria, molds and yeasts. The effectiveness of this preservative and antibacterial agent lies in its ability to penetrate the cell wall of microorganisms and interact with the lipids on the cell membrane, resulting in damage to the structure and function of the cell membrane, thereby inhibiting the growth and reproduction of microorganisms. However, in oily organic solvents, the environment in which sodium methyl parahydroxybenzoate is located is usually a non-polar or weakly polar environment, and its own polarity may affect its solubility and antibacterial activity in organic solvents.

[0012] The antiseptic and antibacterial agent of the present invention is obtained by modifying sodium methyl parahydroxybenzoate with octylphenol polyoxyethylene ether, and the hydrophilic part of octylphenol polyoxyethylene ether can form hydrogen bond with the hydroxyl group of sodium methyl parahydroxybenzoate, while the lipophilic part is compatible with oily solvent. On the one hand, octylphenol polyoxyethylene ether can reduce the interfacial tension of sodium methyl parahydroxybenzoate in oily solvent, thereby improving the dispersion problem of sodium methyl parahydroxybenzoate in oily solvent, making it effectively play the antiseptic and antibacterial effect, and then helping to improve the therapeutic effect of pentoxacillin injection. On the other hand, octylphenol polyoxyethylene ether can increase the solubility of poorly soluble drugs, wrap drug molecules by forming stable micellar structure, improve the solubility and stability of drugs in oily solvent, and prevent the drug from being degraded or precipitated during storage and use.

[0013] 3. The surface modifier of the present invention is preferably a composition of polyvinyl pyrrolidone, hydroxyethyl cellulose and polyethylene glycol. Polyvinyl pyrrolidone can increase the solubility of pentoxacillin in organic solvents, and its non-ionic properties make it less likely to interact with drugs, which helps to maintain the stability of the drug. Hydroxyethyl cellulose can help control the release rate of the drug in the body, and the gel-like structure formed can form a drug reservoir at the injection site, thereby achieving sustained release of the drug. In oily organic solvents, polyethylene glycol can be used as a lubricant to reduce the friction between the drug and biological tissues, thereby reducing irritation to tissues and reducing animal stress. In addition, the applicant can reduce the viscosity of the drug solution, improve the fluidity and injection performance of the drug, and reduce pain and discomfort during injection by regulating the ratio of polyvinyl pyrrolidone, hydroxyethyl cellulose and polyethylene glycol.

[0014] 4. The surfactant of the present invention can reduce the interfacial tension between the active component and the organic solvent, making it easier for poorly soluble drugs such as pentothaline to disperse in oily solvents to form a stable solution. This solubilization effect helps to improve the solubility and bioavailability of the drug.

[0015] 5. The stabilizer of the present invention can maintain the acid-base balance of the injection solution, ensuring the stability and biological activity of the drug. At the same time, the stabilizer can form a stable chelate with metal ions in the body to prevent these metal ions from having adverse effects on the activity of the drug.

[0016] 6. The thixotropic agent of the present invention is hydrophobic fumed silica, whose hydrophobic group can interact with the hydrophobic part in the oily solvent, which helps to disperse pentocillin in the oily solvent, thereby improving the uniformity and bioavailability of the drug. In addition, the unique three-dimensional network structure of hydrophobic fumed silica makes the injection liquid show a higher viscosity at rest or under low shear force, and the viscosity drops rapidly when high shear force is applied, which is convenient for injection operation.

[0017] 7. The antioxidants butylated hydroxytoluene and butylated hydroxyanisole of the present invention capture free radicals and block the chain of oxidation reactions, thereby protecting the active components from oxidative degradation, thereby helping to maintain the chemical stability of the injection, extend its shelf life, and ensure that the drug remains active during storage and use. On the other hand, butylated hydroxyanisole also has certain antibacterial properties, and can cooperate with antiseptics and antibacterial agents to effectively inhibit the growth of certain bacteria and molds, thereby protecting the injection from microbial contamination. In addition, antioxidants can keep the injection active under high temperature conditions, are suitable for injection preparation processes that require high temperature sterilization, and also reduce the storage cost of the injection in the later stage. In addition, the applicant has found that introducing antioxidants into injection preparations can play an anti-discoloration role after long-term storage. This may be because its free radical scavenging ability and metal ion chelation can avoid discoloration caused by oxidation of oily components, thereby enhancing the stability of the injection.

[0018] 8. The local anesthetic of the present invention can block the sodium ion channels on the nerve cell membrane and inhibit the conduction of nerve impulses, thereby producing a local anesthetic effect in the injection area, alleviating the pain caused by mastitis in dairy cows, improving the comfort of dairy cows during treatment, and reducing the stress response caused by pain, thereby improving the compliance of treatment. In addition, in addition to having a local anesthetic effect, local anesthetics (such as lidocaine) are also known to have a certain anti-inflammatory effect. It can inhibit the release of inflammatory mediators and alleviate local inflammatory reactions, and has a certain auxiliary effect on the treatment of mastitis.

[0019] In some embodiments, the organic solvent is propylene glycol dicaprylate / dicaprate and caprylic / capric triglyceride.

[0020] Preferably, the mass ratio of propylene glycol dicaprylate / dicaprate to caprylic / capric triglyceride is 1:(1-3).

[0021] In some embodiments, the surfactant is any one or more of lecithin, Tween 80, Span 80 and polyethylene glycol stearate.

[0022] Preferably, the surfactant is lecithin and Tween 80.

[0023] Further preferably, the surfactant is lecithin and Tween 80 in a mass ratio of 1:2.

[0024] In some embodiments, the stabilizer is citric acid or sodium citrate.

[0025] In some embodiments, the surface modifier is at least two of polyvinyl pyrrolidone, hydroxyethyl cellulose and polyethylene glycol.

[0026] Preferably, the surface modifier is a combination of polyvinyl pyrrolidone, hydroxyethyl cellulose and polyethylene glycol.

[0027] More preferably, the surface modifier is polyvinyl pyrrolidone, hydroxyethyl cellulose and polyethylene glycol in a mass ratio of (2-3):1:1.

[0028] In some embodiments, the method for preparing the antiseptic and antibacterial agent comprises the following preparation steps:

[0029] S1. Sodium methyl paraben and propylene glycol are added to reaction vessel 1, heated to 70-85°C, stirred, and solution 1 is prepared for standby use; octylphenol polyoxyethylene ether and methanol are added to reaction vessel 2, heated to 45-55°C, stirred, and solution 2 is prepared for standby use;

[0030] S2. Add solution 2 dropwise into solution 1, heat to 50-60°C and stir to react for 12-24 hours, wash, and dry to obtain an antiseptic and antibacterial agent.

[0031] In some embodiments, the molar ratio of octylphenol polyoxyethylene ether to sodium methyl paraben is 1:(1-2).

[0032] In some embodiments, the local anesthetic is any one or more of lidocaine, bupivacaine, tetracaine, procaine, and mepivacaine.

[0033] In some embodiments, the thixotropic agent is hydrophobic fumed silica.

[0034] In some embodiments, the antioxidant is butylated hydroxytoluene and / or butylated hydroxyanisole.

[0035] Another aspect of the present invention provides a method for preparing a suspension injection for treating cow mastitis, comprising the following steps:

[0036] (1) adding active ingredients, surfactants, wetting and dispersing agents, surface modifiers, thixotropic agents, preservatives and antibacterial agents, antioxidants and local anesthetics into a container and stirring to obtain a mixture;

[0037] (2) adding an organic solvent to the mixture obtained in step (1), stirring, packaging, and sterilizing to obtain a suspension injection.

[0038] Compared with the prior art, the present invention has the following beneficial effects:

[0039] 1. The suspension injection product of the present invention has stable product quality, and various indicators are not affected; it reduces the stress of dairy cows, has a high absorption rate in the dairy cow body, has a good therapeutic effect on dairy cow mastitis, and has good application value.

[0040] 2. The antiseptic and antibacterial agent of the present invention is obtained by modifying sodium methyl parahydroxybenzoate with octylphenol polyoxyethylene ether, which not only improves the dispersion problem of sodium methyl parahydroxybenzoate in oily solvents, but also octylphenol polyoxyethylene ether can form a stable micelle structure to encapsulate other drug molecules, thereby increasing the solubility and stability of poorly soluble drugs.

[0041] 3. The present invention uses an organic solvent as a carrier of pentoxil or pentoxil hydroiodide, which can not only improve the stability and therapeutic effect of the drug, but also increase the safety of the drug, while providing more formulation flexibility.

[0042] 4. The surface modifier of the present invention can not only improve the solubility and stability of the drug, but also improve the release characteristics, biocompatibility and injection performance of the drug, thereby improving the safety and effectiveness of the drug.

[0043] 5. The thixotropic hydrophobic fumed silica of the present invention not only improves the thixotropy and stability of the injection, but also helps to improve the dispersibility and injection performance of the drug, thereby improving the overall performance and therapeutic effect of the drug.

[0044] 6. The antioxidant of the present invention helps to maintain the chemical stability and antibacterial properties of the injection, so that the injection is resistant to discoloration and can remain active under high temperature conditions.

[0045] 7. The local anesthetic of the present invention can relieve the pain of dairy cows caused by mastitis, reduce the stress response caused by pain, thereby improving treatment compliance, and has a certain synergistic auxiliary effect on the treatment of mastitis. DETAILED DESCRIPTION

[0046] The present invention will be described below in conjunction with specific embodiments. It should be noted that the following embodiments are examples of the present invention and are only used to illustrate the present invention, rather than to limit the present invention. Other combinations and various modifications within the concept of the present invention may be performed without departing from the spirit or scope of the present invention.

[0047] According to the ratios of the raw materials and the preparation methods specified in the following examples and comparative examples, various suspension injections were prepared.

[0048] In order to facilitate those skilled in the art to implement the present invention, some raw material manufacturers of the embodiments and comparative examples are described as follows:

[0049] Tween 80: purchased from Hai'an Petrochemical Plant, Jiangsu Province;

[0050] Hydrophobic fumed silica: purchased from Shanghai Zhenlishi Network Technology Co., Ltd., model R974;

[0051] Polyvinyl pyrrolidone: purchased from Jinan Pengduo Trading Co., Ltd., model 30;

[0052] Polyethylene glycol: purchased from Hai'an Petrochemical Plant, Jiangsu Province, model PEG-200;

[0053] Octylphenol polyoxyethylene ether OP-10: purchased from Yixing Jiateng Chemical Co., Ltd.;

[0054] Other raw materials are not specially specified and can be purchased from the market.

[0055] Preparation Example 1

[0056] The preparation method of the antiseptic and antibacterial agent A comprises the following steps:

[0057] S1. 0.75 mol sodium methyl paraben and 135 ml propylene glycol were added to reaction vessel 1, heated to 75 ° C, stirred for 30 min, and solution 1 was obtained for standby use; 0.5 mol octylphenol polyoxyethylene ether OP-10 and 300 ml methanol were added to reaction vessel 2, heated to 50 ° C, stirred for 60 min, and solution 2 was obtained for standby use;

[0058] S2. Add solution 2 dropwise into solution 1, heat to 55°C, stir and react for 16 hours, wash twice with acetone, and vacuum dry at 85°C for 6 hours to obtain preservative and antibacterial agent A.

[0059] Preparation Example 2

[0060] The preparation method of the antiseptic and antibacterial agent B comprises the following steps:

[0061] S1. 0.75 mol sodium methyl paraben and 135 ml propylene glycol were added to reaction vessel 1, heated to 75 ° C, stirred for 30 min, and solution 1 was obtained for standby use; 0.25 mol octylphenol polyoxyethylene ether OP-10 and 120 ml methanol were added to reaction vessel 2, heated to 50 ° C, stirred for 60 min, and solution 2 was obtained for standby use;

[0062] S2. Add solution 2 dropwise into solution 1, heat to 55°C, stir and react for 16 hours, wash twice with acetone, and vacuum dry at 85°C for 6 hours to obtain preservative and antibacterial agent B.

[0063] Preparation Example 3

[0064] The preparation method of the antiseptic and antibacterial agent C comprises the following steps:

[0065] S1. 0.75 mol sodium methyl paraben and 135 ml propylene glycol were added to reaction vessel 1, heated to 75 ° C, stirred for 30 min, and solution 1 was obtained for standby use; 1 mol octylphenol polyoxyethylene ether OP-10 and 120 ml methanol were added to reaction vessel 2, heated to 50 ° C, stirred for 60 min, and solution 2 was obtained for standby use;

[0066] S2. Add solution 2 dropwise into solution 1, heat to 55°C, stir and react for 16 hours, wash twice with acetone, and vacuum dry at 85°C for 6 hours to obtain preservative and antibacterial agent C.

[0067] Example 1

[0068] A suspension injection for treating mastitis in dairy cows comprises the following raw materials in parts by weight: 6 parts of pentoxacillin hydroiodide, 30 parts of propylene glycol dicaprylate / dicaprate, 60 parts of caprylic / capric triglyceride, 2 parts of lecithin, 4 parts of Tween 80, 1.5 parts of polyvinyl pyrrolidone, 0.75 parts of hydroxyethyl cellulose, 0.75 parts of polyethylene glycol PEG-200, 1.5 parts of citric acid, 1 part of preservative and antibacterial agent A, 0.5 parts of hydrophobic fumed silica, 0.35 parts of butylated hydroxyanisole and 0.3 parts of lidocaine.

[0069] The preparation method of the suspension injection of this embodiment comprises the following steps:

[0070] (1) adding pentosan hydroiodide, lecithin, Tween 80, polyvinyl pyrrolidone, hydroxyethyl cellulose, polyethylene glycol PEG-200, citric acid, preservative and antibacterial agent A, hydrophobic fumed silica, butylated hydroxyanisole and lidocaine into a container and stirring for 30 minutes to obtain a mixture;

[0071] (2) Add propylene glycol dicaprylate / dicaprate and caprylic / capric triglyceride to the mixture obtained in step (1), stir for 60 minutes, divide into portions, and sterilize to obtain a suspension injection.

[0072] Example 2

[0073] A suspension injection for treating mastitis in dairy cows comprises the following raw materials in parts by weight: 4 parts of pentoxacillin hydroiodide, 26.7 parts of propylene glycol dicaprylate / dicaprate, 53.4 parts of caprylic / capric triglyceride, 1.35 parts of lecithin, 2.7 parts of Tween 80, 1.2 parts of polyvinyl pyrrolidone, 0.4 parts of hydroxyethyl cellulose, 0.4 parts of polyethylene glycol PEG-2000, 1 part of sodium citrate, 0.5 parts of preservative and antibacterial agent A, 0.2 parts of hydrophobic fumed silica, 0.2 parts of butylated hydroxytoluene and 0.2 parts of bupivacaine.

[0074] The preparation method of the suspension injection of this embodiment comprises the following steps:

[0075] (1) adding pentosan hydroiodide, lecithin, Tween 80, polyvinyl pyrrolidone, hydroxyethyl cellulose, polyethylene glycol PEG-200, sodium citrate, preservative and antibacterial agent A, hydrophobic fumed silica, butylated hydroxytoluene and bupivacaine into a container and stirring for 30 minutes to obtain a mixture;

[0076] (2) Add propylene glycol dicaprylate / dicaprate and caprylic / capric triglyceride to the mixture obtained in step (1), stir for 60 minutes, divide into portions, and sterilize to obtain a suspension injection.

[0077] Example 3

[0078] A suspension injection for treating mastitis in dairy cows comprises the following raw materials in parts by weight: 8 parts of pentoxacillin hydroiodide, 33.3 parts of propylene glycol dicaprylate / dicaprate, 66.6 parts of caprylic / capric triglyceride, 2.65 parts of lecithin, 5.3 parts of Tween 80, 2.2 parts of polyvinyl pyrrolidone, 0.88 parts of hydroxyethyl cellulose, 0.88 parts of polyethylene glycol PEG-200, 2 parts of citric acid, 1.5 parts of preservative and antibacterial agent A, 0.8 parts of hydrophobic fumed silica, 0.5 parts of butylated hydroxyanisole and 0.4 parts of lidocaine.

[0079] The preparation method of the suspension injection in this example is the same as that in Example 1.

[0080] Example 4

[0081] A suspension injection for treating bovine mastitis and a preparation method thereof, wherein the specific implementation manner is the same as that of Example 1, except that an equal amount of an antiseptic and antibacterial agent B is used to replace an antiseptic and antibacterial agent A.

[0082] Example 5

[0083] A suspension injection for treating mastitis in dairy cows and a preparation method thereof. The specific implementation manner is the same as that of Example 1, except that an equal amount of an antiseptic and antibacterial agent C is used to replace an antiseptic and antibacterial agent A.

[0084] Example 6

[0085] A suspension injection for treating bovine mastitis and a preparation method thereof, wherein the specific implementation manner is the same as that of Example 1, except that an equal amount of sodium methyl parahydroxybenzoate is used to replace the preservative and antibacterial agent A.

[0086] Example 7

[0087] A suspension injection for treating mastitis in dairy cows and a preparation method thereof. The specific implementation manner is the same as that of Example 1, except that 3 parts of polyvinyl pyrrolidone are used to replace 1.5 parts of polyvinyl pyrrolidone, 0.75 parts of hydroxyethyl cellulose and 0.75 parts of polyethylene glycol PEG-200.

[0088] Example 8

[0089] A suspension injection for cow mastitis and a preparation method thereof, wherein the specific implementation manner is the same as that of Example 1, except that an equal amount of ascorbic acid is used to replace butylated hydroxyanisole.

[0090] Example 9

[0091] A suspension injection for treating bovine mastitis and a preparation method thereof. The specific implementation manner is the same as that of Example 1, except that 90 parts of propylene glycol dicaprylate / dicaprate are used to replace 30 parts of propylene glycol dicaprylate / dicaprate and 60 parts of caprylic / capric triglyceride.

[0092] Comparative Example 1

[0093] A suspension injection for treating bovine mastitis and a preparation method thereof. The specific implementation manner is the same as that of Example 1, except that 90 parts of deionized water are used to replace 30 parts of propylene glycol dicaprylate / dicaprate and 60 parts of caprylic / capric triglyceride.

[0094] Comparative Example 2

[0095] A suspension injection for treating mastitis in dairy cows comprises the following raw materials in parts by weight: 6 parts of pentoxacillin hydroiodide, 30 parts of propylene glycol dicaprylate / dicaprate, 60 parts of caprylic / capric triglyceride, 2 parts of lecithin, 4 parts of Tween 80, 1.5 parts of citric acid, 1 part of preservative and antibacterial agent A, 0.5 parts of hydrophobic fumed silica, 0.35 parts of butylated hydroxyanisole and 0.3 parts of lidocaine.

[0096] The preparation method of the suspension injection of this comparative example comprises the following steps:

[0097] (1) adding pentosan hydroiodide, lecithin, Tween 80, citric acid, preservative and antibacterial agent A, hydrophobic fumed silica, butylated hydroxyanisole and lidocaine into a container and stirring for 30 minutes to obtain a mixture;

[0098] (2) Add propylene glycol dicaprylate / dicaprate and caprylic / capric triglyceride to the mixture obtained in step (1), stir for 60 minutes, divide into portions, and sterilize to obtain a suspension injection.

[0099] Effect evaluation:

[0100] The suspension injections prepared in the above Examples 1-9 and Comparative Examples 1-2 were tested and analyzed, and the specific results are shown in Tables 1 and 2.

[0101] Performance Test:

[0102] (1) Conduct an accelerated test for one month and six months at a temperature of 35°C ± 2°C and a humidity of 75% ± 5%, measure the average particle size, and observe the color appearance.

[0103] Table 1

[0104]

[0105]

[0106] (2) Clinical efficacy test was conducted on Example 1, Example 6 and Comparative Examples 1-2. 60 cows with naturally developed mastitis were randomly divided into 4 groups (weight (600±50) kg), each with 15 cows. The cows were fasted for 16 hours before the test and only had free access to water. The cows were given an intramuscular injection of 0.4 ml per kilogram of body weight, once a day (the drug was an injection solution that had been placed at room temperature for 1 month) for 5 consecutive days. The efficacy was determined based on clinical symptoms, and the evaluation results were divided into 3 categories: ① cured: after treatment, the redness, swelling, heat and pain of the cows disappeared, the clots and flocs in the milk disappeared, the milk color and milk production returned to normal, and there was no recurrence after stopping the drug for more than 7 days; ② effective: the clinical symptoms of the cows disappeared after treatment, but there was a recurrence after stopping the drug; ③ ineffective: the symptoms of the cows did not disappear after treatment, and the condition even continued to deteriorate.

[0107] Table 2

[0108] Serial number Cure rate / % Effectiveness / % Inefficiency / % Example 1 100 100 0 Example 6 80 86.7 13.3 Comparative Example 1 60 73.3 26.7 Comparative Example 2 73.3 80 20

[0109] From the results in Table 1, it can be seen that the suspension injections prepared in Examples 1-3 have uniform dispersibility, good stability, and good market value. From the results in Table 2, it can be seen that Example 1 has a good cure rate.

[0110] Compared with Example 1, in Example 4-5, the molar ratio of octylphenol polyoxyethylene ether OP-10 and sodium methyl parahydroxybenzoate was changed when preparing the preservative and antibacterial agent, resulting in poor dispersibility of sodium methyl parahydroxybenzoate, which in turn affected the antibacterial properties of the suspension injection and caused agglomeration after long-term storage.

[0111] In Example 6, compared with Example 1, an equal amount of sodium methyl parahydroxybenzoate is used to replace the preservative and antibacterial agent A. Sodium methyl parahydroxybenzoate is difficult to be effectively dispersed in the injection, and the antibacterial property is greatly weakened, so that the active components are inactivated, affecting the cure rate.

[0112] Compared with Example 1, Example 7 adopts the addition of a single polyvinyl pyrrolidone, which may cause excessive viscosity to affect dispersibility and further affect stability.

[0113] Compared with Example 1, Example 8 uses an equal amount of ascorbic acid to replace butylated hydroxyanisole, which cannot play a good antioxidant effect in the oily organic solvent, causing the injection solution to have poor stability and discoloration.

[0114] Compared with Example 1, Example 9 uses a single propylene glycol dicaprylate / dicaprate, which may affect the solubility of the active component and further affect the dispersibility and stability of the system.

[0115] Compared with Example 1, Comparative Example 1 uses 90 parts of deionized water to replace the organic solvent, which seriously affects the stability of the injection, causing partial inactivation of the active components and affecting the cure rate.

[0116] Compared with Example 1, Comparative Example 2 does not add a surface modifier, which reduces the dispersibility of the injection solution, thereby not only affecting the injection performance, but also causing animal stress and affecting the cure rate.

[0117] The above is only a preferred embodiment of the present invention and does not constitute any form of limitation to the present application. Although the present application is disclosed as above in the preferred embodiment, it is not intended to limit the present application. Any technician familiar with the profession, without departing from the scope of the technical solution of the present application, using the technical content disclosed above to make slight changes or modifications are equivalent to equivalent implementation cases. However, any simple modifications, equivalent changes and modifications made to the above embodiments based on the technical essence of the present invention without departing from the content of the technical solution of the present invention are still within the scope of the technical solution.

Claims

1. A suspension injection for treating cow mastitis, characterized in that: The invention comprises the following raw materials by weight: 4-8 parts of active components, 80-100 parts of organic solvents, 4-8 parts of surfactants, 2-4 parts of surface modifiers, 1-2 parts of stabilizers, 0.5-1.5 parts of preservatives and antibacterial agents, 0.2-0.8 parts of thixotropic agents, 0.2-0.5 parts of antioxidants and 0.2-0.4 parts of local anesthetics; wherein the active component is pentothaline or pentothaline hydroiodide.

2. A suspension injection for cow mastitis according to claim 1, characterized in that: The organic solvents are propylene glycol dicaprylate / dicaprate and caprylic / capric triglyceride.

3. A suspension injection for cow mastitis according to claim 1, characterized in that: The surfactant is any one or more of lecithin, Tween 80, Span 80 and polyethylene glycol stearate.

4. A suspension injection for cow mastitis according to claim 1, characterized in that: The surface modifier is at least two of polyvinyl pyrrolidone, hydroxyethyl cellulose and polyethylene glycol.

5. A suspension injection for cow mastitis according to claim 1, characterized in that: The preparation method of the antiseptic and antibacterial agent comprises the following preparation steps: S1. Sodium methyl paraben and propylene glycol are added to reaction vessel 1, heated to 70-85°C, stirred, and solution 1 is prepared for standby use; octylphenol polyoxyethylene ether and methanol are added to reaction vessel 2, heated to 45-55°C, stirred, and solution 2 is prepared for standby use; S2. Add solution 2 dropwise into solution 1, heat to 50-60°C and stir to react for 12-24 hours, wash, and dry to obtain an antiseptic and antibacterial agent.

6. A suspension injection for cow mastitis according to claim 5, characterized in that: The molar ratio of the octylphenol polyoxyethylene ether to sodium methyl paraben is 1:(1-2).

7. A suspension injection for cow mastitis according to claim 1, characterized in that: The local anesthetic is any one or more of lidocaine, bupivacaine, tetracaine, procaine and mepivacaine.

8. A suspension injection for cow mastitis according to claim 1, characterized in that: The thixotropic agent is hydrophobic fumed silica.

9. A suspension injection for cow mastitis according to claim 1, characterized in that: The antioxidant is butylated hydroxytoluene and / or butylated hydroxyanisole.

10. A method for preparing the suspension injection for cow mastitis according to any one of claims 1 to 9, characterized in that: The following steps are included: (1) adding active ingredients, surfactants, wetting and dispersing agents, surface modifiers, thixotropic agents, preservatives and antibacterial agents, antioxidants and local anesthetics into a container and stirring to obtain a mixture; (2) adding an organic solvent to the mixture obtained in step (1), stirring, packaging, and sterilizing to obtain a suspension injection.